Niki BioSolutions signs ATM sales agreement with H.C. Wainwright for up to $1,396,000 of common stock

Aptorum Group Ltd

Sales Agreement dated October 9, 2026 lets Niki BioSolutions (NIKI) sell up to $1,396,000 of common stock through H.C. Wainwright as sales agent or principal.
Wainwright earns a 3.0% placement fee on gross sales as agent; Brookline Capital Markets acts as qualified independent underwriter for no additional compensation.
Director and largest shareholder Dr. Kira Sheinerman is a Wainwright managing director, creating a FINRA Rule 5121 conflict; Wainwright cannot sell to discretionary accounts without written approval.
Offering falls under a Form S-3 shelf (File No. 333-298608) declared effective October 9, 2026; exhibits include the Sales Agreement (1.1) and Hunter Taubman Fischer & Li opinion (5.1).

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.